Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease

The use of erythropoiesis-stimulating agents (ESAs) reduces the need for recurrent blood transfusions in patients with advanced kidney disease. Rarely, allergic reactions to recombinant human erythropoietin can develop, complicating anemia management due to cross-reactivity between these agents. We...

Full description

Saved in:
Bibliographic Details
Published inCurēus (Palo Alto, CA) Vol. 15; no. 6; p. e40424
Main Authors Panchal, Hemali, Ali, Saiyed, Hallett, Rosemary, Young, Brian, Wiegley, Nasim
Format Journal Article
LanguageEnglish
Published United States Cureus Inc 14.06.2023
Cureus
Subjects
Allergies
Allergy/Immunology
Anaphylaxis
Anemia
Blood transfusions
Case reports
Drug dosages
Immunology
Internal Medicine
Kidney diseases
Medicine
Nephrology
Patients
Sacramento California
United States > US
California
chronic kidney disease (ckd)
anemia of chronic diseases
drug-induced hypersensitivity
synthetic epo
desensitization therapy
Online AccessGet full text

Cover

More Information
Summary:The use of erythropoiesis-stimulating agents (ESAs) reduces the need for recurrent blood transfusions in patients with advanced kidney disease. Rarely, allergic reactions to recombinant human erythropoietin can develop, complicating anemia management due to cross-reactivity between these agents. We report the use of an outpatient desensitization protocol, which was successfully completed in an adult patient who developed a maculopapular rash as a form of delayed-type hypersensitivity reaction (DTH) to epoetin-alfa (EPO) use, followed by successful re-introduction of EPO and continued tolerance.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.40424